Novo Nordisk’s semaglutide is expected to become the world’s biggest selling drug in 2025, via Ozempic in type 2 diabetes (T2D) and Wegovy in obesity, but the Danish company’s celebrations may be muted.
Lilly Has The Upper Hand In Obesity In 2025 But Novo Has More Cards To Play
A flurry of big readouts are expected in the supercharged obesity/diabetes space, with Novo Nordisk looking to make up ground against its rival Eli Lilly.
More from Alimentary/Metabolic
• By
The obesity market leader has unveiled its second deal in days, paying $75m upfront for a potential first-in-class ACSL5 inhibitor, while the deal also provides some respite for Lexicon.
• By
The company is planning to launch oxylanthanum carbonate for chronic kidney disease patients on dialysis with hyperphosphatemia.
• By
After a long wait for patients, Vykat has become the first drug approved for Prader-Willi syndrome symptoms, opening the market up for Soleno and future challengers.
• By
The obesity market leader is teaming up with China’s United Bio-Technology to develop a product they believe could beat Lilly’s late-stage same-class candidate retatrutide.
More from R&D
• By
The Danish firm is spending nearly $580m to repurchase up to 2.2 million shares
• By
The Texas-based firm is giving up on the investigational Alzheimer’s therapy after a second Phase III failure left it with nowhere to go in the disease.
• By
A decision from the FDA is due by 28 September.